Laboratory robotics maker Opentrons has secured $40 million in a Series E round, the company announced on October 29, 2026, with the funding aimed squarely at three goals: AI-driven experimental execution, extended automation capabilities, and expansion into new markets and geographies. Healthcare investor Avego led the round, with participation from BroadOak Capital Partners. Opentrons says the capital will fund its next growth phase, in which its AI and robotics systems work together to design, execute, and learn from experiments required to achieve customers' scientific goals.

Opentrons' Foundation: The Flex and OT-2 Robotics Platforms

The funding lands on an established installed base. Opentrons' product line centers on two programmable robots, the Flex and the OT-2, which resemble small, transparent laboratory cabinets housing robotic workstations. The company also sells AI software tools for automating sample preparation and other repetitive experimental work.

The Flex is the more advanced of the two: an enclosed benchtop robot that transfers small volumes of liquid between samples. Because it can work on more samples at once and use an optional robotic gripper to move plates, more steps of an experiment can run without human intervention. On the software side, Opentrons' tools target common high-throughput lab work, including next-generation sequencing, PCR, proteomics, and nucleic acid extraction, according to the company's product pages.

Pillar 1: Accelerating AI-Driven Experimental Execution

The first investment pillar builds on what Opentrons already sells. Its OpentronsAI software lets researchers use natural language to design, simulate, optimize, and verify protocols, while the drag-and-drop Protocol Designer allows protocol construction without code. The company describes its ecosystem as intelligent, AI-enabled software for designing, visualizing, and refining protocols.

The Series E is meant to scale this layer so that AI can run experiments directly on the robots. In the announcement, Opentrons framed the ambition explicitly: "We made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons." The company points to researchers such as Gabe Gomes at Carnegie Mellon University leveraging AI to automate scientific discovery as an example of the direction it is enabling.

Pillar 2: Expanding Automation Capabilities and Infrastructure

The second pillar directs capital at Opentrons' robotics, software, and data infrastructure. Per the announcement, the Series E will allow the company to scale its robotics, software, and data infrastructure tools to standardize laboratory automation, including AI software tools for automating sample preparation and other repetitive experimental work, and systems built for AI to run experiments directly.

In practical terms, that means extending what the Flex and OT-2 can do in the physical lab — more automated steps, more instruments under software control — while tightening the connection between protocol design and execution. James Flexner, Managing Partner at Avego, underscored the rationale: "Every AI-driven discovery still has to be tested in a real lab." The investment therefore targets the bottleneck between computational discovery and physical validation.

Pillar 3: Strategic Market Expansion

The third pillar is commercial: Opentrons states the funding will support expansion into new markets and geographies. The company's stated mission is to standardize laboratory automation, and broader reach serves that goal directly — the more labs running Opentrons robots, the more standardized the automated workflows become.

Avego's Flexner framed the demand side of that expansion, noting that "Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data," and that the investor sees "a significant opportunity for autonomous science to converge around Opentrons' platform." The company already counts major pharmaceutical companies and research universities among its customers, with more than 11,000 robots deployed globally.

Opentrons' $40M Investment Strategy: Pillars of Autonomous Science

The table below maps each stated investment pillar to the concrete Opentrons technology it touches and the outcome the company says scientists should expect. All goals are as described by Opentrons in its funding announcement and product materials; they have not been independently tested.

How Opentrons says its $40M Series E will be deployed
Investment PillarRelated Opentrons TechnologyIntended Outcome for Scientists
AI-driven experimental executionOpentronsAI (natural-language protocol design, simulation, optimization, verification); AI-enabled software ecosystem built to run experiments directlyAI and robotics systems working together to design, execute, and learn from experiments needed for customers' scientific goals
Extended automation capabilitiesFlex and OT-2 robots; instruments and data infrastructure across the platformFaster protocol development, expanded robot and instrument capabilities, deeper integration into the broader lab automation ecosystem
Market expansionFull hardware and software platform, deployed across 11,000+ robotsStandardized automation accessible to more labs in new markets and geographies

Read together, the three pillars form a single loop: AI designs the experiment, robots execute it in the physical lab, and the resulting data feeds the next design cycle. That loop — not any individual product — is what Opentrons means by "autonomous science," and it is the standardization target the new capital is meant to accelerate.

Outlook: Opentrons' Path to Autonomous Science

Opentrons is positioned to accelerate the development and adoption of AI-driven laboratory automation, aiming to standardize "autonomous science" in biotech research. The announced goals are the company's own; no independent assessment of its financial health, competitive position, or the technical performance of its AI tools accompanies the announcement, and no specific new products beyond the stated investment areas have been disclosed.

For labs and researchers tracking whether the funding delivers, the concrete test is observable: monitor future product announcements, software updates, and reported research outcomes demonstrating AI-driven experimental execution and expanded market presence. Evidence that OpentronsAI-driven experiments are running end-to-end on Flex and OT-2 systems in newly entered geographies would indicate the Series E is converting its stated pillars into the standardized autonomous science it promises.

Sources